• Jin Deng, Maha Balouch, Michael Albrink, and Enrico M Camporesi.
• From the Morsani College of Medicine, University of South Florida, Tampa, TEAMHealth Anesthesia, Tampa, Florida, and the Division of General Surgery, Tampa General Hospital, Tampa, Florida.
• South. Med. J. 2021 Oct 1; 114 (10): 644-648.

ObjectiveThis study blindly evaluated sugammadex compared with neostigmine on length of stay in the postanesthesia care unit (PACU).MethodsFifty patients undergoing elective laparoscopic cholecystectomy or abdominal wall hernia repair consented to receive either sugammadex (2 mg/kg) or neostigmine (0.07 mg/kg) for the reversal of rocuronium neuromuscular blockade. Reversal agents were administered during surgical closing, and the train of four was measured until a twitch ratio of T4:T1 ≥ 0.9 was obtained to signify a robust reversal. Postreversal outcomes also were measured during PACU stay. Aldrete scores, pain visual analog scale score, and nausea were measured during the PACU stay.ResultsPatients receiving sugammadex experienced a shorter PACU stay at the time of discharge than patients receiving neostigmine, by an average of 12 minutes (P < 0.05).ConclusionsSugammadex patients had a significantly shorter PACU stay.

21 keywords...

hide…